Evidence map›Paper›PMID 26246566›Full record

ArticleJournal of virology2015

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Joyce K Hu, Jordan C Crampton, Albert Cupo, Thomas Ketas, Marit J van Gils, Kwinten Sliepen, Steven W de Taeye, Devin Sok, Gabriel Ozorowski, Isaiah Deresa and 7 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.

  1. Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Joyce K HuDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA.
Jordan C CramptonDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA.
Albert CupoDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Thomas KetasDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Marit J van GilsDepartment of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Kwinten SliepenDepartment of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Steven W de TaeyeDepartment of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Devin SokCenter for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts, USA.
Gabriel OzorowskiCenter for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Isaiah DeresaDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA.
Robyn StanfieldDepartment of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA.
Andrew B WardCenter for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Dennis R BurtonCenter for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts, USA.
Per Johan KlasseDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Rogier W SandersDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
John P MooreDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Shane CrottyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA shane@lji.org.
Cornell University · USInternational AIDS Vaccine Initiative · USLa Jolla Institute for Immunology · USUniversity of Amsterdam · NLRagon Institute of MGH, MIT and Harvard · USScripps Research Institute · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
NIAID NIH HHS UM1 AI100663PHS HHS UM1-AL100663
6 · The paper itself

Abstract

unlabelledGenerating neutralizing antibodies (nAbs) is a major goal of many current HIV-1 vaccine efforts. To be of practical value, these nAbs must be both potent and cross-reactive in order to be capable of preventing the transmission of the highly diverse and generally neutralization resistant (Tier-2) HIV-1 strains that are in circulation. The HIV-1 envelope glycoprotein (Env) spike is the only target for nAbs. To explore whether Tier-2 nAbs can be induced by Env proteins, we immunized conventional mice with soluble BG505 SOSIP.664 trimers that mimic the native Env spike. Here, we report that it is extremely difficult for murine B cells to recognize the Env epitopes necessary for inducing Tier-2 nAbs. Thus, while trimer-immunized mice raised Env-binding IgG Abs and had high-quality T follicular helper (Tfh) cell and germinal center (GC) responses, they did not make BG505.T332N nAbs. Epitope mapping studies showed that Ab responses in mice were specific to areas near the base of the soluble trimer. These areas are not well shielded by glycans and likely are occluded on virions, which is consistent with the lack of BG505.T332N nAbs. These data inform immunogen design and suggest that it is useful to obscure nonneutralizing epitopes presented on the base of soluble Env trimers and that the glycan shield of well-formed HIV Env trimers is virtually impenetrable for murine B cell receptors (BCRs). IMPORTANCE: Human HIV vaccine efficacy trials have not generated meaningful neutralizing antibodies to circulating HIV strains. One possible hindrance has been the lack of immunogens that properly mimic the native conformation of the HIV envelope trimer protein. Here, we tested the first generation of soluble, native-like envelope trimer immunogens in a conventional mouse model. We attempted to generate neutralizing antibodies to neutralization-resistant circulating HIV strains. Various vaccine strategies failed to induce neutralizing antibodies to a neutralization-resistant HIV strain. Further analysis revealed that mouse antibodies targeted areas near the bottom of the soluble envelope trimers. These areas are not easily accessible on the HIV virion due to occlusion by the viral membrane and may have resulted from an absence of glycan shielding. Our results suggest that obscuring the bottom of soluble envelope trimers is a useful strategy to reduce antibody responses to epitopes that are not useful for virus neutralization.

Indexed as

AnimalsAntibodies, NeutralizingAntibody SpecificityAntigens, ViralB-Lymphocytesenv Gene Products, Human Immunodeficiency VirusEpitope MappingEpitopesGene ExpressionHEK293 CellsHIV-1HIV AntibodiesHIV InfectionsHumansImmunizationImmunoglobulin GAntibodies, NeutralizingAntigens, Viralenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesImmunoglobulin GReceptors, Antigen, B-CellRecombinant Proteins

Identifiers

PMID26246566
PMCPMC4580201
OpenAlexW1920682071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.